Stockreport
Allogene Therapeutics Announces Participation in the TD Cowen 5th Annual Oncology Innovation Summit
![GlobeNewswire](../../../Content/images/providers/GN.png)
Last allogene therapeutics, inc. earnings: 2/27 04:30 am
Check Earnings Report
SOUTH SAN FRANCISCO, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced it will participate in the TD Cowen 5th Annual Oncology Innovation Summit. TD Cowen 5th Annual Oncology Innovation SummitTuesday, May 28, 20249:30am PT/12:30pm ET The webcast will be posted to the Company's website at www.allogene.com under the Investors tab in the News and Events section. Following a live webcast, a replay will be available on the Company's website for approximately 30 days. About Allogene TherapeuticsAllogene Therapeutics, with headquarters in?South San Francisco, is a clinical-stage?biotechnology company pioneering the development of allogeneic chimeric antigen receptor T?cell (AlloCAR T™) products for cancer and autoimmune disease. Led by a management team with significant?experience in cell therapy
[Read more]
IMPACT SNAPSHOT | EVENT TIME: | ALLO | ||||
---|---|---|---|---|---|---|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
LAST PRICE | ||
VWAP | ||
High:
|
MAX UP |
High:
|
Low:
|
MAX DOWN |
Low:
|
%
|
POST NEWS RANGE |
%
|
|
PRICE CHANGE |
|
|
PRICE CHANGE PERCENTAGE |
|
|
S&P 500 (SPX) |
|
%
|
VOLUME RATIO |
%
|
VOLUME (SHARES) | ||
TICKS | ||
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
ALLO alerts
ALLO alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALLO alerts
High impacting Allogene Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ALLO
NEWS
NEWS
- Allogene Therapeutics (ALLO) Down 13.9% Since Last Earnings Report: Can It Rebound? [Yahoo! Finance][Yahoo! Finance]
- Allogene Therapeutics, Inc. (NASDAQ: ALLO) is now covered by analysts at Piper Sandler. They set an "overweight" rating and a $11.00 price target on the stock.[MarketBeat]
- Allogene Therapeutics Announces Participation in the TD Cowen 5th Annual Oncology Innovation Summit [Yahoo! Finance][Yahoo! Finance]
- Allogene Therapeutics, Inc. (NASDAQ: ALLO) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $14.00 to $13.00. They now have an "outperform" rating on the stock.[MarketBeat]
- Allogene Therapeutics, Inc. (NASDAQ: ALLO) had its price target lowered by analysts at HC Wainwright from $10.00 to $9.00. They now have a "buy" rating on the stock.[MarketBeat]
- More
ALLO
SEC Filings
SEC Filings
- 6/11/24 - Form 3
- 6/10/24 - Form 8-K
- 6/7/24 - Form 4
- ALLO's page on the SEC website
- More